Catalyst OrthoScience’s total shoulder systems offer precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue. Credit: joel bubble ben / Shutterstock.

US-based medical technology company Catalyst OrthoScience has secured $20m in equity and venture debt financing.

The funding round included contributions from RC Capital, Mutual Capital Partners, and Bridge Bank.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This financial boost comes from the company surpassing 10,000 total shoulder arthroplasty (TSA) procedures. This significant milestone underscores its growth potential and commitment to innovation in the shoulder arthroplasty market.

The company is poised for the next phase of commercial adoption. This funding will enable Catalyst to expand its distribution channels, invest in talent and training, introduce new products, and strengthen its position as a leading innovator in the sector.

According to Catalyst CEO Carl O’Connell, the company has made substantial progress since its first case in 2016.

He said: “Our unique ability to blend true innovation with unmatched efficiency and predictable outcomes is transforming an industry that has long been burdened by solutions that introduce inefficiencies and inflate procedural costs without also delivering improved patient outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“At Catalyst, we’re closing those gaps with our single-tray systems, proprietary instrumentation, fewer surgical steps, and purposefully designed implants.”

He also noted the growing need for such solutions in ambulatory surgery centres (ASCs) where reducing case turnaround times and sterilisation costs is crucial.

RC Capital managing partner and Catalyst board member Carter McNabb commented on the company’s growth prospects: “Catalyst is a unique company in a fast-growing sector. This funding will allow the company to further its mission to improve shoulder arthroplasty for surgeons and patients across the continuum of care.”

Founded by orthopaedic surgeon Steven Goldberg, Catalyst OrthoScience aims to revolutionise shoulder replacement surgery with less invasive techniques, fewer complications, and a more natural-feeling shoulder post-surgery.

The company’s total shoulder systems are designed for precision and accuracy in shoulder restoration, preserving the patient’s bone and soft tissue.

In August 2021, Catalyst OrthoScience launched its Archer 3D Targeting imaging software, enhancing preoperative planning for shoulder arthroplasty.